ATE397019T1 - Herstellung von f(ab')2 fragmenten in saügetierzelle - Google Patents
Herstellung von f(ab')2 fragmenten in saügetierzelleInfo
- Publication number
- ATE397019T1 ATE397019T1 AT02789019T AT02789019T ATE397019T1 AT E397019 T1 ATE397019 T1 AT E397019T1 AT 02789019 T AT02789019 T AT 02789019T AT 02789019 T AT02789019 T AT 02789019T AT E397019 T1 ATE397019 T1 AT E397019T1
- Authority
- AT
- Austria
- Prior art keywords
- fragments
- preparation
- mammal cells
- cells
- antibody fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL0100917 | 2001-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397019T1 true ATE397019T1 (de) | 2008-06-15 |
Family
ID=19760784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02789019T ATE397019T1 (de) | 2001-12-17 | 2002-12-17 | Herstellung von f(ab')2 fragmenten in saügetierzelle |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050048038A1 (de) |
| EP (1) | EP1456238B1 (de) |
| AT (1) | ATE397019T1 (de) |
| AU (1) | AU2002353662B2 (de) |
| CA (1) | CA2470579C (de) |
| DE (1) | DE60226896D1 (de) |
| DK (1) | DK1456238T3 (de) |
| ES (1) | ES2307807T3 (de) |
| NZ (1) | NZ533332A (de) |
| SI (1) | SI1456238T1 (de) |
| WO (1) | WO2003051927A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| AU2002351444B2 (en) | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| CA2470579C (en) | 2001-12-17 | 2012-03-06 | Crucell Holland B.V. | Production of f(ab')2 fragments in mammalian cells |
| ATE414144T1 (de) | 2003-05-09 | 2008-11-15 | Crucell Holland Bv | Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon |
| MA49426B1 (fr) | 2017-10-02 | 2022-09-30 | Laboratorios Silanes S A De C V | Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2 |
| WO2023205656A2 (en) * | 2022-04-18 | 2023-10-26 | John Paul Ii Medical Research Institute | Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| DE3584341D1 (de) * | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JP3951062B2 (ja) * | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| WO1997000326A1 (en) * | 1995-06-15 | 1997-01-03 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| PT1161548E (pt) * | 1999-04-15 | 2005-06-30 | Crucell Holland Bv | Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus |
| EP1103610A1 (de) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Impfstoffherstellung von immortalisierten Säugetierzellinien |
| EP1130099A1 (de) * | 2000-02-25 | 2001-09-05 | Crucell Holland B.V. | Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper |
| CA2470579C (en) | 2001-12-17 | 2012-03-06 | Crucell Holland B.V. | Production of f(ab')2 fragments in mammalian cells |
-
2002
- 2002-12-17 CA CA2470579A patent/CA2470579C/en not_active Expired - Lifetime
- 2002-12-17 DE DE60226896T patent/DE60226896D1/de not_active Expired - Lifetime
- 2002-12-17 WO PCT/NL2002/000841 patent/WO2003051927A2/en not_active Ceased
- 2002-12-17 AU AU2002353662A patent/AU2002353662B2/en not_active Ceased
- 2002-12-17 US US10/499,298 patent/US20050048038A1/en not_active Abandoned
- 2002-12-17 SI SI200230701T patent/SI1456238T1/sl unknown
- 2002-12-17 AT AT02789019T patent/ATE397019T1/de active
- 2002-12-17 DK DK02789019T patent/DK1456238T3/da active
- 2002-12-17 EP EP02789019A patent/EP1456238B1/de not_active Expired - Lifetime
- 2002-12-17 NZ NZ533332A patent/NZ533332A/en not_active IP Right Cessation
- 2002-12-17 ES ES02789019T patent/ES2307807T3/es not_active Expired - Lifetime
-
2008
- 2008-02-14 US US12/070,145 patent/US7537916B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003051927A3 (en) | 2003-11-20 |
| DK1456238T3 (da) | 2008-08-18 |
| US7537916B2 (en) | 2009-05-26 |
| AU2002353662B2 (en) | 2009-04-23 |
| SI1456238T1 (sl) | 2008-08-31 |
| NZ533332A (en) | 2005-07-29 |
| DE60226896D1 (de) | 2008-07-10 |
| EP1456238A2 (de) | 2004-09-15 |
| EP1456238B1 (de) | 2008-05-28 |
| US20080166767A1 (en) | 2008-07-10 |
| CA2470579C (en) | 2012-03-06 |
| WO2003051927A2 (en) | 2003-06-26 |
| ES2307807T3 (es) | 2008-12-01 |
| US20050048038A1 (en) | 2005-03-03 |
| CA2470579A1 (en) | 2003-06-26 |
| AU2002353662A1 (en) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200001946T2 (tr) | Aşı | |
| EP1362093A4 (de) | Schnellproduktion monoklonaler antikörper | |
| TR200602095T2 (tr) | Hümanize Anti-LT-Beta-R antikorları | |
| ATE405647T1 (de) | Rekombinantes gelatin in impstoffen | |
| ATE397019T1 (de) | Herstellung von f(ab')2 fragmenten in saügetierzelle | |
| DK1443961T3 (da) | Glycoprotein-sammensætninger | |
| CY1105772T1 (el) | Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια | |
| DK0977874T3 (da) | Svækket salmonella-stamme anvendt som bæremedium til oral immunisering | |
| TR200102338T2 (tr) | Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar. | |
| DK1157037T3 (da) | GCSF-konjugater | |
| DE60144145D1 (de) | Subtilisin-variante | |
| AR032394A1 (es) | Una composicion oral. | |
| BR0109346A (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas | |
| BR0113162A (pt) | Ariloxialquilaminas nao-imidazóis | |
| BR0215266A (pt) | Preparação liofilizada compreendendo anticorpos contra o receptor de egf | |
| IL172854A0 (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
| WO2002010337A3 (en) | Method of cloning porcine animals | |
| PT1451302E (pt) | Folhas reconstituídas in vitro de epitélio corneal humano e método de produção das mesmas | |
| PT1200561E (pt) | Clone celular recombinante estavel, sua producao e utilizacao | |
| NO20031860L (no) | Kahalalid F | |
| NO20061470L (no) | Fremgangsmate for fremstilling av gamma-karboksylerte proteiner | |
| PL367306A1 (pl) | Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania | |
| WO2002022573A3 (en) | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies | |
| TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
| ATE522223T1 (de) | Pflanzenextrakte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1456238 Country of ref document: EP |